Cinnarizine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Motion sickness Initial: 30 mg 2 hours before travel, then 15 mg 8 hourly during the journey if necessary. Cerebrovascular disorders 25 mg tid. Vertigo and vestibular disorders; Nausea and vertigo caused by Meniere's disease 30 mg tid. Peripheral circulatory disorder 50-75 mg bid to tid. Max: 225 mg daily.
Dosage Details
Oral
Motion sickness
Adult: Initially, 30 mg 2 hours before travel, then 15 mg 8 hourly during the journey if necessary.
Child: 5-12 years Initially, 15 mg 2 hours before travel, then 7.5 mg 8 hourly during the journey if necessary. >12 years Same as adult dose.

Oral
Nausea and vertigo caused by Meniere's disease, Vertigo and vestibular disorders
Adult: 30 mg tid.
Child: 5-12 years 15 mg tid. >12 years Same as adult dose.

Oral
Cerebrovascular disorders
Adult: 25 mg tid.

Oral
Peripheral circulatory disorders
Adult: 50-75 mg bid to tid. Max: 225 mg daily.
Administration
Should be taken with food.
Special Precautions
Patient with hypotension (high dose), Parkinson's disease and porphyria. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Epigastric discomfort.
Gastrointestinal disorders: Nausea, dyspepsia, vomiting, upper abdominal pain, gastrointestinal discomfort.
General disorders and administration site conditions: Fatigue, lethargy.
Hepatobiliary disorders: Cholestatic jaundice.
Investigations: Increased weight.
Musculoskeletal and connective tissue disorders: Muscle rigidity.
Nervous system disorders: Dyskinesia, extrapyramidal disorder, Parkinsonism, tremor, drowsiness, somnolence.
Skin and subcutaneous tissue disorders: Hyperhidrosis, lichenoid keratosis (e.g. lichen planus), subacute cutaneous lupus erythematosus.
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Overdosage
Symptoms: Consciousness alterations ranging from somnolence to stupor and coma, vomiting, extrapyramidal symptoms, hypotonia; seizures (young children). Management: Symptomatic and supportive treatment. May consider administration of activated charcoal within 1 hour of ingestion.
Drug Interactions
May potentiate sedative effects of CNS depressants and TCAs.
Food Interaction
May enhance sedative effects with alcohol.
Lab Interference
May prevent positive reactions to dermal reactivity indicators if used within 4 days prior to skin testing.
Action
Description: Cinnarizine is a piperazine derivative and a non-competitive antagonist of smooth muscle contractions caused by vasoactive agents like histamine. It has antihistamine, sedative, and Ca-channel blocking activity. It inhibits contraction of smooth muscle by selectively inhibiting Ca influx into depolarised cells, thereby reducing free Ca ions available for the induction and maintenance of contraction.
Pharmacokinetics:
Absorption: Slowly absorbed. Time to peak plasma concentration: 4 hours.
Distribution: Plasma protein binding: 91%.
Metabolism: Extensively metabolised mainly by CYP2D6.
Excretion: Via faeces (mainly as unchanged drug) and urine (as metabolites). Elimination half-life: 3-6 hours.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 30°C.
ATC Classification
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Disclaimer: This information is independently developed by MIMS based on Cinnarizine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Celenid
  • Cinnaron
  • Nazin
  • Pharmaniaga Cinnarizine
  • Uphageron
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in